Review

crispr dna design tool (ATUM Bio)

ATUM Bio is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATUM Bio crispr dna design tool

Specificity and efficiency evaluation of the <t>CRISPR</t> molecular system with pUC19 mutagens and the pCDH GFP gene. A) and B) Detailed information of all <t>DNA‐RNP</t> possible combinations for pUC19 mutated amplicons and pCDH amplicons analyzed by agarose gel electrophoresis. C) and D) TAE agarose gel electrophoresis analysis of CRISPR‐cleavage products for the pUC19‐0.3k and pUC19‐0.8k groups, related to Figure . E) TAE agarose gel electrophoresis of CRISPR‐cleavage products for the pCDH‐2k and pCDH‐5k groups, related to Figure . F) In vitro binding assays for evaluating the efficiency of CRISPR/dCas9 using CRISPR‐magnetic beads (MBs). G, H) Capture efficiency of different target sites calculated using the qPCR Ct results from Figure , Supporting Information, (* p < 0.05, ** p < 0.01, two‐tailed t ‐test, n = 3; error bars represent standard deviations). I) TAE agarose gel electrophoresis analysis evaluate the capture efficiency of GFP DNA samples using dRNP‐functionalized beads and treated with different post‐release methods. A DNA molecular weight marker ranging from 100 bp to 5000 bp was applied in all agarose electrophoresis runs.

Crispr Dna Design Tool, supplied by ATUM Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/crispr+dna+design+tool/crispr+gdna+design+tool/pmc09108660-182-50-46
Average 90 stars, based on 1 article reviews

crispr dna design tool - by Bioz Stars, 2026-09

90/100 stars

Images

1) Product Images from "A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification"

Article Title: A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

Journal: Advanced Science

doi: 10.1002/advs.202105231

Specificity and efficiency evaluation of the CRISPR molecular system with pUC19 mutagens and the pCDH GFP gene. A) and B) Detailed information of all DNA‐RNP possible combinations for pUC19 mutated amplicons and pCDH amplicons analyzed by agarose gel electrophoresis. C) and D) TAE agarose gel electrophoresis analysis of CRISPR‐cleavage products for the pUC19‐0.3k and pUC19‐0.8k groups, related to Figure . E) TAE agarose gel electrophoresis of CRISPR‐cleavage products for the pCDH‐2k and pCDH‐5k groups, related to Figure . F) In vitro binding assays for evaluating the efficiency of CRISPR/dCas9 using CRISPR‐magnetic beads (MBs). G, H) Capture efficiency of different target sites calculated using the qPCR Ct results from Figure , Supporting Information, (* p < 0.05, ** p < 0.01, two‐tailed t ‐test, n = 3; error bars represent standard deviations). I) TAE agarose gel electrophoresis analysis evaluate the capture efficiency of GFP DNA samples using dRNP‐functionalized beads and treated with different post‐release methods. A DNA molecular weight marker ranging from 100 bp to 5000 bp was applied in all agarose electrophoresis runs.

Figure Legend Snippet: Specificity and efficiency evaluation of the CRISPR molecular system with pUC19 mutagens and the pCDH GFP gene. A) and B) Detailed information of all DNA‐RNP possible combinations for pUC19 mutated amplicons and pCDH amplicons analyzed by agarose gel electrophoresis. C) and D) TAE agarose gel electrophoresis analysis of CRISPR‐cleavage products for the pUC19‐0.3k and pUC19‐0.8k groups, related to Figure . E) TAE agarose gel electrophoresis of CRISPR‐cleavage products for the pCDH‐2k and pCDH‐5k groups, related to Figure . F) In vitro binding assays for evaluating the efficiency of CRISPR/dCas9 using CRISPR‐magnetic beads (MBs). G, H) Capture efficiency of different target sites calculated using the qPCR Ct results from Figure , Supporting Information, (* p < 0.05, ** p < 0.01, two‐tailed t ‐test, n = 3; error bars represent standard deviations). I) TAE agarose gel electrophoresis analysis evaluate the capture efficiency of GFP DNA samples using dRNP‐functionalized beads and treated with different post‐release methods. A DNA molecular weight marker ranging from 100 bp to 5000 bp was applied in all agarose electrophoresis runs.

Techniques Used: CRISPR, Agarose Gel Electrophoresis, In Vitro, Binding Assay, Magnetic Beads, Two Tailed Test, Molecular Weight, Marker, Electrophoresis

A,B) SPR angular spectra of the dRNP‐functionalized CRISPR‐SPR‐Chips detecting DNA fragments that contain different target sites. C,D) SPR signals generated by CRISPR‐SPR‐Chips with or without a graphdiyne layer immobilized with different loaded amounts of dCas9 protein. E,F) Recombinant pUC19 amplicons (0.8 kb) were detected by the corresponding dRNP‐functionalized CRISPR‐SPR‐Chi(ps (Origin, Mut1, Mut2, and Mut3). G,H) The pCDH amplicons of 5 kb were detected by the dRNP‐functionalized CRISPR‐SPR‐Chips with different target sites (GFP‐Pos1, GFP‐Pos2, and GFP‐Pos3).

Figure Legend Snippet: A,B) SPR angular spectra of the dRNP‐functionalized CRISPR‐SPR‐Chips detecting DNA fragments that contain different target sites. C,D) SPR signals generated by CRISPR‐SPR‐Chips with or without a graphdiyne layer immobilized with different loaded amounts of dCas9 protein. E,F) Recombinant pUC19 amplicons (0.8 kb) were detected by the corresponding dRNP‐functionalized CRISPR‐SPR‐Chi(ps (Origin, Mut1, Mut2, and Mut3). G,H) The pCDH amplicons of 5 kb were detected by the dRNP‐functionalized CRISPR‐SPR‐Chips with different target sites (GFP‐Pos1, GFP‐Pos2, and GFP‐Pos3).

Techniques Used: CRISPR, Generated, Recombinant

Real‐time SPR response of the dRNP‐functionalized CRISPR‐SPR‐Chips used to monitor the kinetic process of DNA fragments binding to the corresponding dRNP‐functionalized CRISPR‐SPR‐Chips. A, B) Binding kinetics of recombinant pUC19 amplicons (0.3 kb and 0.8 kb). C, D) Binding kinetics of pCDH amplicons (2 kb and 5 kb). (E) Binding kinetics of the pUC19‐Mut3‐0.8k amplicons in concentrations ranging from 1.6 ng µL −1 to 1000 ng µL −1 . (F) Binding kinetics of the pCDH‐GFP‐Pos2‐5k amplicons in concentrations ranging from 1.6 ng µL −1 to 1000 ng µL −1 . G, H) Limit of detection (LOD) test of pUC19‐Mut3‐0.8k and pCDH‐GFP‐Pos2‐5k amplicons ( n = 3; error bars represent standard deviations).

Figure Legend Snippet: Real‐time SPR response of the dRNP‐functionalized CRISPR‐SPR‐Chips used to monitor the kinetic process of DNA fragments binding to the corresponding dRNP‐functionalized CRISPR‐SPR‐Chips. A, B) Binding kinetics of recombinant pUC19 amplicons (0.3 kb and 0.8 kb). C, D) Binding kinetics of pCDH amplicons (2 kb and 5 kb). (E) Binding kinetics of the pUC19‐Mut3‐0.8k amplicons in concentrations ranging from 1.6 ng µL −1 to 1000 ng µL −1 . (F) Binding kinetics of the pCDH‐GFP‐Pos2‐5k amplicons in concentrations ranging from 1.6 ng µL −1 to 1000 ng µL −1 . G, H) Limit of detection (LOD) test of pUC19‐Mut3‐0.8k and pCDH‐GFP‐Pos2‐5k amplicons ( n = 3; error bars represent standard deviations).

Techniques Used: CRISPR, Binding Assay, Recombinant

Figure Legend Snippet: Kinetic constants for the interaction of the CRISPR‐SPR‐Chip and DNA analytes

Techniques Used: CRISPR

Analysis of healthy and DMD clinical samples for DMD‐associated dystrophin exon 7 and exon 47 deletions using CRISPR‐SPR‐Chips. A) Schematic of the dystrophin gene (DMD) with target exons. B) Results of CRISPR‐SPR‐Chip analysis for the deletion (absence) of targeted exons (+) in healthy and DMD clinical samples. C) Change in angle obtained from the SPR measurement of the dRNP‐DMD7‐CRISPR‐SPR‐Chip with patient sample A1 using gradient concentrations. D) Negative signal threshold of CRISPR‐SPR‐Chips. E) Change in angle obtained from the SPR measurement of the dRNP‐DMD7‐CRISPR‐SPR‐Chip with all samples. The negative signal threshold is the result from panel D. F) Change in angle obtained from the SPR measurement of the dRNP‐DMD47‐CRISPR‐SPR‐Chip with all samples. The negative signal threshold is the result from panel D. All data were collected from three independent experiments (*** p < 0.001, two‐tailed t ‐test, n = 3; error bars represent standard deviations).

Figure Legend Snippet: Analysis of healthy and DMD clinical samples for DMD‐associated dystrophin exon 7 and exon 47 deletions using CRISPR‐SPR‐Chips. A) Schematic of the dystrophin gene (DMD) with target exons. B) Results of CRISPR‐SPR‐Chip analysis for the deletion (absence) of targeted exons (+) in healthy and DMD clinical samples. C) Change in angle obtained from the SPR measurement of the dRNP‐DMD7‐CRISPR‐SPR‐Chip with patient sample A1 using gradient concentrations. D) Negative signal threshold of CRISPR‐SPR‐Chips. E) Change in angle obtained from the SPR measurement of the dRNP‐DMD7‐CRISPR‐SPR‐Chip with all samples. The negative signal threshold is the result from panel D. F) Change in angle obtained from the SPR measurement of the dRNP‐DMD47‐CRISPR‐SPR‐Chip with all samples. The negative signal threshold is the result from panel D. All data were collected from three independent experiments (*** p < 0.001, two‐tailed t ‐test, n = 3; error bars represent standard deviations).

Techniques Used: CRISPR, Two Tailed Test

other:

Article Title: Robust CRISPR/Cas9 mediated genome editing tool for banana and plantain (Musa spp.)
Article Snippet: Two gRNAs were designed from the conserved region of exon 5 and 6 of A genome and exon 2 and 3 of B genome using ATUM CRISPR DNA Jo ur na l P re -p ro f Design Tool (https://www.atum.bio).

Recombinant:

Article Title: A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification
Article Snippet: .. All of the sgRNAs targeting recombinant pUC19 [New England Biolabs (NEB), Ipswich, MA, USA] vectors (Origin, Mut1, Mut2, and Mut3), the green fluorescent protein (GFP) sequence in the pCDH (NEB) vector (GFP‐Pos1, GFP‐Pos2, and GFP‐Pos3), and exons 7 and 47 of human DMD were designed using DNA 2.0 (now ATUM) CRISPR DNA design tool. .. The sgRNAs were designed in accordance with the mutated and unmutated sequences, and used to form CRISPR‐sgRNA complexes (RNPs) with Cas9 nuclease ( S. pyogenes ; NEB) are referred to as RNP‐Origin, RNP‐Mut1, RNP‐Mut2, and RNP‐Mut3.

Sequencing:

CRISPR:

Image Search Results

Journal: Advanced Science

Article Title: A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

doi: 10.1002/advs.202105231

Figure Lengend Snippet: Specificity and efficiency evaluation of the CRISPR molecular system with pUC19 mutagens and the pCDH GFP gene. A) and B) Detailed information of all DNA‐RNP possible combinations for pUC19 mutated amplicons and pCDH amplicons analyzed by agarose gel electrophoresis. C) and D) TAE agarose gel electrophoresis analysis of CRISPR‐cleavage products for the pUC19‐0.3k and pUC19‐0.8k groups, related to Figure . E) TAE agarose gel electrophoresis of CRISPR‐cleavage products for the pCDH‐2k and pCDH‐5k groups, related to Figure . F) In vitro binding assays for evaluating the efficiency of CRISPR/dCas9 using CRISPR‐magnetic beads (MBs). G, H) Capture efficiency of different target sites calculated using the qPCR Ct results from Figure , Supporting Information, (* p < 0.05, ** p < 0.01, two‐tailed t ‐test, n = 3; error bars represent standard deviations). I) TAE agarose gel electrophoresis analysis evaluate the capture efficiency of GFP DNA samples using dRNP‐functionalized beads and treated with different post‐release methods. A DNA molecular weight marker ranging from 100 bp to 5000 bp was applied in all agarose electrophoresis runs.

Article Snippet: All of the sgRNAs targeting recombinant pUC19 [New England Biolabs (NEB), Ipswich, MA, USA] vectors (Origin, Mut1, Mut2, and Mut3), the green fluorescent protein (GFP) sequence in the pCDH (NEB) vector (GFP‐Pos1, GFP‐Pos2, and GFP‐Pos3), and exons 7 and 47 of human DMD were designed using DNA 2.0 (now ATUM) CRISPR DNA design tool.

Techniques: CRISPR, Agarose Gel Electrophoresis, In Vitro, Binding Assay, Magnetic Beads, Two Tailed Test, Molecular Weight, Marker, Electrophoresis

Journal: Advanced Science

Article Title: A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

doi: 10.1002/advs.202105231

Figure Lengend Snippet: A,B) SPR angular spectra of the dRNP‐functionalized CRISPR‐SPR‐Chips detecting DNA fragments that contain different target sites. C,D) SPR signals generated by CRISPR‐SPR‐Chips with or without a graphdiyne layer immobilized with different loaded amounts of dCas9 protein. E,F) Recombinant pUC19 amplicons (0.8 kb) were detected by the corresponding dRNP‐functionalized CRISPR‐SPR‐Chi(ps (Origin, Mut1, Mut2, and Mut3). G,H) The pCDH amplicons of 5 kb were detected by the dRNP‐functionalized CRISPR‐SPR‐Chips with different target sites (GFP‐Pos1, GFP‐Pos2, and GFP‐Pos3).

Techniques: CRISPR, Generated, Recombinant

Journal: Advanced Science

Article Title: A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

doi: 10.1002/advs.202105231

Figure Lengend Snippet: Real‐time SPR response of the dRNP‐functionalized CRISPR‐SPR‐Chips used to monitor the kinetic process of DNA fragments binding to the corresponding dRNP‐functionalized CRISPR‐SPR‐Chips. A, B) Binding kinetics of recombinant pUC19 amplicons (0.3 kb and 0.8 kb). C, D) Binding kinetics of pCDH amplicons (2 kb and 5 kb). (E) Binding kinetics of the pUC19‐Mut3‐0.8k amplicons in concentrations ranging from 1.6 ng µL −1 to 1000 ng µL −1 . (F) Binding kinetics of the pCDH‐GFP‐Pos2‐5k amplicons in concentrations ranging from 1.6 ng µL −1 to 1000 ng µL −1 . G, H) Limit of detection (LOD) test of pUC19‐Mut3‐0.8k and pCDH‐GFP‐Pos2‐5k amplicons ( n = 3; error bars represent standard deviations).

Techniques: CRISPR, Binding Assay, Recombinant

Journal: Advanced Science

Article Title: A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

doi: 10.1002/advs.202105231

Figure Lengend Snippet: Kinetic constants for the interaction of the CRISPR‐SPR‐Chip and DNA analytes

Techniques: CRISPR

Journal: Advanced Science

Article Title: A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification

doi: 10.1002/advs.202105231

Figure Lengend Snippet: Analysis of healthy and DMD clinical samples for DMD‐associated dystrophin exon 7 and exon 47 deletions using CRISPR‐SPR‐Chips. A) Schematic of the dystrophin gene (DMD) with target exons. B) Results of CRISPR‐SPR‐Chip analysis for the deletion (absence) of targeted exons (+) in healthy and DMD clinical samples. C) Change in angle obtained from the SPR measurement of the dRNP‐DMD7‐CRISPR‐SPR‐Chip with patient sample A1 using gradient concentrations. D) Negative signal threshold of CRISPR‐SPR‐Chips. E) Change in angle obtained from the SPR measurement of the dRNP‐DMD7‐CRISPR‐SPR‐Chip with all samples. The negative signal threshold is the result from panel D. F) Change in angle obtained from the SPR measurement of the dRNP‐DMD47‐CRISPR‐SPR‐Chip with all samples. The negative signal threshold is the result from panel D. All data were collected from three independent experiments (*** p < 0.001, two‐tailed t ‐test, n = 3; error bars represent standard deviations).

Techniques: CRISPR, Two Tailed Test

Review

crispr dna design tool (ATUM Bio)

Structured Review

Images

1) Product Images from "A Highly Sensitive CRISPR‐Empowered Surface Plasmon Resonance Sensor for Diagnosis of Inherited Diseases with Femtomolar‐Level Real‐Time Quantification"

Related Articles

other:

Recombinant:

Sequencing:

CRISPR:

Similar Products

Image Search Results